265 related articles for article (PubMed ID: 25468044)
1. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
Cheng W; Zhu S; Ma X; Qiu N; Peng P; Sheng R; Hu Y
Eur J Med Chem; 2015 Jan; 89():826-34. PubMed ID: 25462282
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1
Cheng W; Wang S; Yang Z; Tian X; Hu Y
Drug Des Devel Ther; 2019; 13():3079-3089. PubMed ID: 31695326
[TBL] [Abstract][Full Text] [Related]
5. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
[TBL] [Abstract][Full Text] [Related]
6. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
9. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
12. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
14. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
15. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
[TBL] [Abstract][Full Text] [Related]
16. Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
Wang Z; Wu X; Wang L; Zhang J; Liu J; Song Z; Tang Z
Bioorg Med Chem Lett; 2016 Jun; 26(11):2589-93. PubMed ID: 27118497
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
Hu M; Ye W; Li J; Zhong G; He G; Xu Q; Zhang Y
Chem Biol Drug Des; 2015 Mar; 85(3):280-9. PubMed ID: 24954438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
